Year All2024202320222021 Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023 02-24-2023 Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023 02-23-2023 CORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics 02-22-2023 KemPharm Enhances Senior Management Team 01-31-2023 KemPharm Issues Letter to Shareholders 01-24-2023 KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy 01-18-2023 KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer 01-11-2023 KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company 01-09-2023 KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) 12-21-2022 KemPharm Announces Appointment of Christopher Posner as New Independent Director 11-29-2022
Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023 02-24-2023
Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023 02-23-2023
KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy 01-18-2023
KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer 01-11-2023
KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company 01-09-2023
KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) 12-21-2022